White matter abnormalities in schizophrenia patients with tardive dyskinesia: A diffusion tensor image study

Schizophrenia Research

Volumn 109, Issue 1-3, 2009, Pages 167-181

  Bai, Ya Mei ^a,b   Chou, Kun Hsien ^b   Lin, Ching Po ^b   Chen, I Yun ^b   Li, Cheng Ta ^a   Yang, Kai Chun ^a   Chou, Yuan Hwa ^a,b   Su, Tung Ping ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Schizophrenia; Tardive dyskinesia; White matter

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; FLUNARIZINE; FLUPENTIXOL; HALOPERIDOL; OLANZAPINE; RISPERIDONE; SERTINDOLE; SULPIRIDE;

ADULT; ARTICLE; BRAIN MALFORMATION; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSION TENSOR IMAGING; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM; TARDIVE DYSKINESIA; WHITE MATTER;

ADULT; ANISOTROPY; ANTIPSYCHOTIC AGENTS; BRAIN; BRAIN MAPPING; DIFFUSION MAGNETIC RESONANCE IMAGING; DYSKINESIA, DRUG-INDUCED; FEMALE; FRONTAL LOBE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TEMPORAL LOBE;

EID: 62649133735     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2009.02.003     Document Type: Article

References (71)

1. Agartz I., Andersson J.L., and Skare S. Abnormal brain white matter in schizophrenia: a diffusion tensor imaging study. NeuroReport 12 (2001) 2251-2254
2. Akbarian S., Kim J.J., Potkin S.G., Hetrick W.P., Bunney W.E., and Jones E.G. Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients. Arch. Gen. Psychiatry 53 (1996) 425-436
3. Alexander G.E., and Crutcher M.D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13 (1990) 266-271
4. Ascher-Svanum H., Zhu B., Faries D., Peng X., Kinon B.J., and Tohen M. Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study. J. Clin. Psychiatry (2008) e1-e9
5. Bai Y.M., Yu S.C., and Lin C.C. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 64 (2003) 1342-1348
6. Bai Y.M., Yu S.C., Chen J.Y., Lin C.Y., Chou P., and Lin C.C. Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study. Int. Clin. Psychopharmacol. 20 (2005) 79-85
7. Bartels M., and Themelis J. Computerized tomography in tardive dyskinesia. Evidence of structural abnormalities in the basal ganglia system. Arch. Psychiatr. Nervenkr. 233 (1983) 371-379
8. Bartzokis G., Garber H.J., Marder S.R., and Olendorf W.H. MRI in tardive dyskinesia: shortened left caudate T2. Biol. Psychiatry 28 (1990) 1027-1036
9. Berry K., Drake R., Stewart C., Aitkin L.M., Byrne J., Barrowclough C., and Purandare N. Orofacial dyskinesia, frontal lobe dysfunction, and coping in older people with psychosis. Am. J. Geriatr. Psychiatry 15 (2007) 800-806
10. Bhatia T., Sabeeha M.R., Shriharsh V., Garg K., Segman R.H., Uriel H.L., Strous R., Nimgaonkar V.L., Bernard L., and Deshpande S.N. Clinical and familial correlates of tardive dyskinesia in India and Israel. J. Postgrad. Med. 50 (2004) 167-172
11. Brown K.W., and White T. The association among negative symptoms, movement disorders, and frontal lobe psychological deficits in schizophrenic patients. Biol. Psychiatry 30 (1991) 1182-1190
12. Buckley P., O'Callaghan E., Mulvany F., Larkin C., Stack J.P., Redmond O., Ennis J.T., Thompson P., and Waddington J.L. Basal ganglia T2 relaxation times in schizophrenia: a quantitative magnetic resonance imaging study in relation to tardive dyskinesia. Psychiatry Res. 61 (1995) 95-102
13. Casey D.E. Pathophysiology of antipsychotic drug-induced movement disorders. J. Clin. Psychiatry 65 Suppl 9 (2004) 25-28
14. Chen J.Y., Bai Y.M., Pyng L.Y., and Lin C.C. Risperidone for tardive dyskinesia. Am. J. Psychiatry 158 (2001) 1931-1932
15. Chouinard G. Interrelations between psychiatric symptoms and drug-induced movement disorder. J. Psychiatry Neurosci. 31 (2006) 177-180
16. Christensen J., Holcomb J., and Garver D.L. State-related changes in cerebral white matter may underlie psychosis exacerbation. Psychiatry Res. 130 (2004) 71-78
17. Correll C.U., and Schenk E.M. Tardive dyskinesia and new antipsychotics. Curr. Opin. Psychiatry 21 (2008) 151-156
18. Cortese L., Caligiuri M.P., Malla A.K., Manchanda R., Takhar J., and Haricharan R. Relationship of neuromotor disturbances to psychosis symptoms in first-episode neuroleptic-naive schizophrenia patients. Schizophr. Res. 75 (2005) 65-75
19. Dalgalarrondo P., and Gattaz W.F. Basal ganglia abnormalities in tardive dyskinesia. Possible relationship with duration of neuroleptic treatment. Eur. Arch. Psychiatry Clin. Neurosci. 244 (1994) 272-277
20. Eberhard J., Lindstrom E., and Levander S. Tardive dyskinesia and antipsychotics: a 5-year longitudinal study of frequency, correlates and course. Int. Clin. Psychopharmacol. 21 (2006) 35-42
21. Elkashef A.M., Buchanan R.W., Gellad F., Munson R.C., and Breier A. Basal ganglia pathology in schizophrenia and tardive dyskinesia: an MRI quantitative study. Am. J. Psychiatry 151 (1994) 752-755
22. Garver D.L., Holcomb J.A., and Christensen J.D. Compromised myelin integrity during psychosis with repair during remission in drug-responding schizophrenia. Int. J. Neuropsychopharmacol. (2007) 1-13
23. Gebhardt S., Hartling F., Hanke M., Theisen F.M., von Georgi R., Grant P., Mittendorf M., Martin M., Fleischhaker C., Schulz E., and Remschmidt H. Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia. Eur. Child Adolesc. Psychiatry 17 (2008) 44-53
24. Gold J.M., Egan M.F., Kirch D.G., Goldberg T.E., Daniel D.G., Bigelow L.B., and Wyatt R.J. Tardive dyskinesia: neuropsychological, computerized tomographic, and psychiatric symptom findings. Biol. Psychiatry 30 (1991) 587-599
25. Granholm E., Bartzokis G., Asarnow R.F., and Marder S.R. Preliminary associations between motor procedural learning, basal ganglia T2 relaxation times, and tardive dyskinesia in schizophrenia. Psychiatry Res. 50 (1993) 33-44
26. Graybiel A.M. The basal ganglia and cognitive pattern generators. Schizophr. Bull. 23 (1997) 459-469
27. Gur R.E., Maany V., Mozley P.D., Swanson C., Bilker W., and Gur R.C. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am. J. Psychiatry 155 (1998) 1711-1717
28. Hanson D.R., and Gottesman I.I. Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med. Genet. 6 (2005) 7
29. Harvey I., Ron M.A., Murray R., Lewis S., Barker G., and McManus D. MRI in schizophrenia: basal ganglia and white matter T1 times. Psychol. Med. 21 (1991) 587-598
30. Ho B.C., Andreasen N.C., Nopoulos P., Arndt S., Magnotta V., and Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch. Gen. Psychiatry 60 (2003) 585-594
31. Hof P.R., Haroutunian V., Friedrich V.L., Byne W., Buitron C., Perl D.P., and Davis K.L. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol. Psychiatry 53 (2003) 1075-1085
32. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987) 261-276
33. Keshavan M.S., Rosenberg D., Sweeney J.A., and Pettegrew J.W. Decreased caudate volume in neuroleptic-naive psychotic patients. Am. J. Psychiatry 155 (1998) 774-778
34. Kubicki M., McCarley R., Westin C.F., Park H.J., Maier S., Kikinis R., Jolesz F.A., and Shenton M.E. A review of diffusion tensor imaging studies in schizophrenia. J. Psychiatr. Res. 41 (2007) 15-30
35. Leh S.E., Ptito A., Chakravarty M.M., and Strafella A.P. Fronto-striatal connections in the human brain: a probabilistic diffusion tractography study. Neurosci. Lett. 419 (2007) 113-118
36. Lerner V., Miodownik C., Kaptsan A., Bersudsky Y., Libov I., Sela B.A., and Witztum E. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. J. Clin. Psychiatry 68 (2007) 1648-1654
37. Libov I., Miodownik C., Bersudsky Y., Dwolatzky T., and Lerner V. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. J. Clin. Psychiatry 68 (2007) 1031-1037
38. Lim K.O., and Helpern J.A. Neuropsychiatric applications of DTI - a review. Neuropsychiatr. Appl. NMR Biomed. 15 (2002) 587-593
39. Lin C.C., Bai Y.M., Chen J.Y., Wang Y.C., and Liou Y.J. Treatment of clozapine-associated tardive dyskinesia. Prog. Neuro-psychopharmacol. Biol. Psychiatry 32 2 (2008) 599-600
40. Liou Y.J., Wang Y.C., Lin C.C., Bai Y.M., Lai I.C., Liao D.L., and Chen J.Y. Association analysis of NAD(P)Hratioquinone oxidoreductase (NQO1) Pro187Ser genetic polymorphism and tardive dyskinesia in patients with schizophrenia in Taiwan. Int. J. Neuropsychopharmacol. 8 (2005) 483-486
41. Liou Y.J., Lai I.C., Liao D.L., Chen J.Y., Lin C.C., Lin C.Y., Chen C.M., Bai Y.M., Chen T.T., and Wang Y.C. The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia. Schizophr. Res. 86 (2006) 323-325
42. Liou Y.J., Lai I.C., Lin M.W., Bai Y.M., Lin C.C., Liao D.L., Chen J.Y., Lin C.Y., and Wang Y.C. Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophrenia. Pharmacogenet. Genomics 16 (2006) 151-157
43. Liou Y.J., Wang Y.C., Chen J.Y., Bai Y.M., Lin C.C., Liao D.L., Chen T.T., Chen M.L., Mo G.H., and Lai I.C. Association analysis of polymorphisms in the N-methyl-d-aspartate (NMDA) receptor subunit 2B (GRIN2B) gene and tardive dyskinesia in schizophrenia. Psychiatry Res. 153 (2007) 271-275
44. McCreadie R.G., Thara R., Padmavati R., Srinivasan T.N., and Jaipurkar S.D. Structural brain differences between never-treated patients with schizophrenia, with and without dyskinesia, and normal control subjects: a magnetic resonance imaging study. Arch. Gen. Psychiatry 59 (2002) 332-336
45. McCreadie R.G., Srinivasan T.N., Padmavati R., and Thara R. Extrapyramidal symptoms in unmedicated schizophrenia. J. Psychiatr. Res. 39 (2005) 261-266
46. Miller D.D., McEvoy J.P., Davis S.M., Caroff S.N., Saltz B.L., Chakos M.H., Swartz M.S., Keefe R.S., Rosenheck R.A., Stroup T.S., and Lieberman J.A. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr. Res. 80 (2005) 33-43
47. Minami T., Nobuhara K., Okugawa G., Takase K., Yoshida T., Sawada S., Ha-Kawa S., Ikeda K., and Kinoshita T. Diffusion tensor magnetic resonance imaging of disruption of regional white matter in schizophrenia. Neuropsychobiology 47 (2003) 141-145
48. Mion C.C., Andreasen N.C., Arndt S., Swayze V.W., and Cohen G.A. MRI abnormalities in tardive dyskinesia. Psychiatry Res. 40 (1991) 157-166
49. Mo G.H., Liao D.L., Lai I.C., Wang Y.C., Chen J.Y., Lin C.Y., Chen T.T., Chen M.L., Bai Y.M., Lin C.C., and Liou Y.J. Support for an association of the C939T polymorphism in the human DRD2 gene with tardive dyskinesia in schizophrenia. Schizophr. Res. 97 (2007) 302-304
50. Munetz M.R., and Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp. Community Psychiatr. 39 (1988) 1172-1177
51. Okugawa G., Nobuhara K., Minami T., Tamagaki C., Takase K., Sugimoto T., Sawada S., and Kinoshita T. Subtle disruption of the middle cerebellar peduncles in patients with schizophrenia. Neuropsychobiology 50 (2004) 119-123
52. Okugawa G., Nobuhara K., Sugimoto T., and Kinoshita T. Diffusion tensor imaging study of the middle cerebellar peduncles in patients with schizophrenia. Cerebellum 4 (2005) 123-127
53. Okugawa G., Nobuhara K., Minami T., Takase K., Sugimoto T., Saito Y., Yoshimura M., and Kinoshita T. Neural disorganization in the superior cerebellar peduncle and cognitive abnormality in patients with schizophrenia: a diffusion tensor imaging study. Prog. Neuro-psychopharmacol. Biol. Psychiatry 30 (2006) 1408-1412
54. Pantelis C., Stuart G.W., Nelson H.E., Robbins T.W., and Barnes T.R. Spatial working memory deficits in schizophrenia: relationship with tardive dyskinesia and negative symptoms. Am. J. Psychiatry 158 (2001) 1276-1285
55. Schooler N.R., and Kane J.M. Research diagnoses for tardive dyskinesia. Arch. Gen. Psychiatry 39 (1982) 486-487
56. Schultz W., Tremblay L., and Hollerman J.R. Reward processing in primate orbitofrontal cortex and basal ganglia. Cereb. Cortex 10 (2000) 272-284
57. Shihabuddin L., Buchsbaum M.S., Hazlett E.A., Haznedar M.M., Harvey P.D., Newman A., Schnur D.B., Spiegel-Cohen J., Wei T., Machac J., Knesaurek K., Vallabhajosula S., Biren M.A., Ciaravolo T.M., and Luu-Hsia C. Dorsal striatal size, shape, and metabolic rate in never-medicated and previously medicated schizophrenics performing a verbal learning task. Arch. Gen. Psychiatry 55 (1998) 235-243
58. Simpson G.M., and Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand., Suppl. 212 (1970) 11-19
59. Stephan K.E., Baldeweg T., and Friston K.J. Synaptic plasticity and dysconnection in schizophrenia. Biol. Psychiatry 59 (2006) 929-939
60. Szeszko P.R., Ardekani B.A., Ashtari M., Kumra S., Robinson D.G., Sevy S., Gunduz-Bruce H., Malhotra A.K., Kane J.M., Bilder R.M., and Lim K.O. White matter abnormalities in first-episode schizophrenia or schizoaffective disorder: a diffusion tensor imaging study. Am. J. Psychiatry 162 (2005) 602-605
61. Szymanski S., Gur R.C., Gallacher F., Mozley L.H., and Gur R.E. Vulnerability to tardive dyskinesia development in schizophrenia: an FDG-PET study of cerebral metabolism. Neuropsychopharmacology 15 (1996) 567-575
62. Takase K., Tamagaki C., Okugawa G., Nobuhara K., Minami T., Sugimoto T., Sawada S., and Kinoshita T. Reduced white matter volume of the caudate nucleus in patients with schizophrenia. Neuropsychobiology 50 (2004) 296-300
63. Tenback D.E., van Harten P.N., Slooff C.J., and van Os J. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10, 000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am. J. Psychiatry 163 (2006) 1438-1440
64. Tenback D.E., van Harten P.N., Slooff C.J., and van Os J. Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study. Compr. Psychiatry 48 (2007) 436-440
65. Ueyama K., Fukuzako H., Takeuchi K., Hirakawa K., Fukuzako T., Hokazono Y., Takigawa M., and Matsumoto K. Brain atrophy and intellectual impairment in tardive dyskinesia. Jpn. J. Psychiatry Neurol. 47 (1993) 99-104
66. Uranova N.A., Vostrikov V.M., Orlovskaya D.D., and Rachmanova V.I. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr. Res. 67 (2004) 269-275
67. Volkow N.D., Wolf A.P., Brodie J.D., Cancro R., Overall J.E., Rhoades H., and Van Gelder P. Brain interactions in chronic schizophrenics under resting and activation conditions. Schizophr. Res. 1 (1988) 47-53
68. Waddington J.L., O'Callaghan E., Buckley P., Madigan C., Redmond O., Stack J.P., Kinsella A., Larkin C., and Ennis J.T. Tardive dyskinesia in schizophrenia. Relationship to minor physical anomalies, frontal lobe dysfunction and cerebral structure on magnetic resonance imaging. Br. J. Psychiatry 167 (1995) 41-44
69. Winterer G., and Weinberger D.R. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci. 27 (2004) 683-690
70. Wonodi I., Hong L.E., and Thaker G.K. Psychopathological and cognitive correlates of tardive dyskinesia in patients treated with neuroleptics. Adv. Neurol. 96 (2005) 336-349
71. Zhang X.Y., Tan Y.L., Zhou D.F., Cao L.Y., Wu G.Y., Haile C.N., Kosten T.A., and Kosten T.R. Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. J. Clin. Psychiatry 68 (2007) 754-760